60 degrees pharmaceuticals receives additional u.s. patent covering tafenoquine for prevention of plasmodium falciparum malaria

Washington, aug. 22, 2023 (globe newswire) -- 60 degrees pharmaceuticals (“60p”) (nasdaq: sxtp), specialists in developing and marketing medicines for infectious diseases, today announced that the united states patent and trademark office (uspto) has awarded 60p a patent covering the use of tafenoquine for prevention of plasmodium falciparum malaria. tafenoquine is the active molecule in arakoda ® , the company's fda-approved drug for malaria prevention in individuals aged 18 years and older for up to six months of continuous dosing.
SXTP Ratings Summary
SXTP Quant Ranking